|
by Movik, Espen, Hamidi, Vida, Aaserud, Morten, Neilson, Aileen Rae
Published 2008
“... The evidence base regarding the cost-effectiveness of cetuximab is, at the time of writing, weak, particularly...”Published 2008
Norwegian Knowledge Centre for the Health Services
|
by Movik, Espen, Hamidi, Vida, Natvig Norderhaug, Inger, Klemp, Marianne
Published 2009
“..., with Norwegian cost data associated with the treatment alternatives. Results Mean progression-free time...”Published 2009
Norwegian Knowledge Centre for the Health Services